EZH2 and head and neck squamous cell carcinoma: Collectively, these results indicate that, at least in HNSCC and gastrointestinal cancer, squamocin demonstrates potential therapeutic efficacy against EZH2/MYC axis‐driven tumors without causing significant host toxicity.